芒果苷(MGF)，一种从芒果(Mangifera indica L.)提取的黄酮类化合物，最初被用作一种保健品，现在正在广泛地探索其抗癌潜力。全球的科学家通过验证的体外和体内模型，来研究这种生物活性物质在治疗各种癌症方面的潜力。对于已建立的乳腺癌细胞系如MDA-MB-23、BEAS-2B和MCF-7，这种生物活性物质在体外的抗癌潜力接近许多已批准的合成抗癌药物。然而，这种黄酮类物质的溶解度和生物利用度是主要的挑战，它的口服生物利用度报道不到2%，而其水溶解度也仅为0.111 mg/mL。纳米药物传递系统尝试以所需的速率、所需的量将药物传递到所需的位置。许多研究人员已探索了各种基于纳米技术的方法，以提供对癌症治疗中芒果苷的有效和安全的传递。纳米颗粒被用作载体，封装芒果苷，保护其免受降解，并促进其传递到癌细胞。他们试图利用药物传递方法来增强这种生物活性物质的生物利用度、安全性和疗效。本综述侧重于芒果苷及其衍生物的来源和结构阐明，以及这种生物活性物质的益处。该综述还提供了有关芒果苷的传递相关挑战及其纳米尺寸形式在抗癌方面的应用的见解。此外，还讨论了利用一种相对较新的深度学习方法来解决这种生物活性物质的药代动力学问题。该综述还对芒果苷作为癌症治疗药物的未来希望进行了批判性分析。

Mangiferin (MGF), a xanthone derived from Mangifera indica L., initially employed as a nutraceutical, is now being explored extensively for its anticancer potential. Scientists across the globe have explored this bioactive for managing a variety of cancers using validated in vitro and in vivo models. The in vitro anticancer potential of this biomolecule on well-established breast cancer cell lines such as MDA-MB-23, BEAS-2B cells and MCF-7 is closer to many approved synthetic anticancer agents. However, the solubility and bioavailability of this xanthone are the main challenges, and its oral bioavailability is reported to be less than 2%, and its aqueous solubility is also 0.111 mg/mL. Nano-drug delivery systems have attempted to deliver the drugs at the desired site at a desired rate in desired amounts. Many researchers have explored various nanotechnology-based approaches to provide effective and safe delivery of mangiferin for cancer therapy. Nanoparticles were used as carriers to encapsulate mangiferin, protecting it from degradation and facilitating its delivery to cancer cells. They have attempted to enhance the bioavailability, safety and efficacy of this very bioactive using drug delivery approaches. The present review focuses on the origin and structure elucidation of mangiferin and its derivatives and the benefits of this bioactive. The review also offers insight into the delivery-related challenges of mangiferin and its applications in nanosized forms against cancer. The use of a relatively new deep-learning approach to solve the pharmacokinetic issues of this bioactive has also been discussed. The review also critically analyzes the future hope for mangiferin as a therapeutic agent for cancer management.